| Literature DB >> 34817269 |
Keiichi Torimoto1, Keisuke Okuno1, Ryohei Kuroda1, No'Ad Shanas1, Stephanie M Cicalese1, Kunie Eguchi1, Katherine J Elliott1, Tatsuo Kawai1, Cali B Corbett1, Amanda M Peluzzo1, Amanda K St Paul1, Michael V Autieri1, Rosario Scalia1, Victor Rizzo1, Tomoki Hashimoto2, Satoru Eguchi1.
Abstract
In this study, we have looked for an optimum media glucose concentration and compared glucose consumption in three vascular cell types, endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and adventitial fibroblasts (AFs) with or without angiotensin II (AngII) stimulation. In a subconfluent 6-well experiment in 1 mL DMEM with a standard low (100 mg/dL), a standard high (450 mg/dL), or a mixed middle (275 mg/dL) glucose concentration, steady and significant glucose consumption was observed in all cell types. After 48-h incubation, media that contained low glucose was reduced to almost 0 mg/dL, media that contained high glucose remained significantly higher at ∼275 mg/dL, and media that contained middle glucose remained closer to physiological range. AngII treatment enhanced glucose consumption in AFs and VSMCs but not in ECs. Enhanced extracellular acidification rate by AngII was also observed in AFs. In AFs, AngII induction of target proteins at 48 h varied depending on the glucose concentration used. In low glucose media, induction of glucose regulatory protein 78 or hexokinase II was highest, whereas induction of VCAM-1 was lowest. Utilization of specific inhibitors further suggests essential roles of angiotensin II type-1 receptor and glycolysis in AngII-induced fibroblast activation. Overall, this study demonstrates a high risk of hypo- or hyperglycemic conditions when standard low or high glucose media is used with vascular cells. Moreover, these conditions may significantly alter experimental outcomes. Media glucose concentration should be monitored during any culture experiments and utilization of middle glucose media is recommended for all vascular cell types.Entities:
Keywords: angiotensin II; endothelial cells; fibroblasts; glycolysis; vascular smooth muscle cells
Mesh:
Substances:
Year: 2021 PMID: 34817269 PMCID: PMC8791793 DOI: 10.1152/ajpcell.00257.2021
Source DB: PubMed Journal: Am J Physiol Cell Physiol ISSN: 0363-6143 Impact factor: 5.282